1. Iron overload and chelation therapy in myelodysplastic syndromes
Sally Temraz, Valeria Santini, Khaled Musallam, Ali Taher 
Critical Reviews in Oncology / Hematology 
Volume 91, Issue 1, Pages (July 2014)
DOI: /j.critrevonc
Copyright © 2014 Elsevier Ireland Ltd Terms and Conditions

2. Fig. 1
Mechanism of action of iron chelators in the management of iron overload. TBI: transferrin bound iron; ROS: reactive oxygen species; NTBI: non-transferrin bound iron; TFR-1: transferrin receptor-1; LPI: labile plasma iron; DMT1: divalent metal transporter 1.
Critical Reviews in Oncology / Hematology  , 64-73DOI: ( /j.critrevonc )
Copyright © 2014 Elsevier Ireland Ltd Terms and Conditions

3. Fig. 2
Suggested algorithm for the use of iron chelators in MDS patients. *Contraindications to deferasirox include: creatinine clearance<40ml/min or serum creatinine more than twice the upper limit of normal, platelet counts <50×109/L, severe hepatic impairment (Child–Pugh class C) and hypersensitivity to deferasirox. *Contraindications to deferoxamine include: severe renal failure or anuria, Clcr<10ml/min and hypersensitivity to deferoxamine.
Critical Reviews in Oncology / Hematology  , 64-73DOI: ( /j.critrevonc )
Copyright © 2014 Elsevier Ireland Ltd Terms and Conditions